Pre-Market Review: Delcath Systems Inc., Astex Pharma Inc., BioMarin Pharma Inc., and Akorn Inc. Editor Note: For more information about this release, please scroll to bottom. PR Newswire LONDON, August 21, 2013 LONDON, August 21, 2013 /PRNewswire/ -- The U.S. equity market posted some gains on Tuesday, August 20, 2013. The S&P 500 ended 0.38% higher at 1,652.35, and the NASDAQ Composite closed the day 0.68% higher at 3,613.59. Shares in healthcare companies ended higher, tracking gains in the broader market. The major movers in the sector included Delcath Systems Inc. (NASDAQ: DCTH), Astex Pharmaceuticals (NASDAQ: ASTX), BioMarin Pharmaceuticals Inc. (NASDAQ: BMRN), and Akorn Inc. (NASDAQ: AKRX). AAAResearchReports.com initiated preliminary technical research on DCTH, ASTX, BMRN, and AKRX. These free reports are accessible by signing today at: http://www.aaaresearchreports.com/register/ Shares in Delcath Systems Inc. surged on Tuesday as the broader market ended on a higher note. The company's shares oscillated between $0.30 and $0.34 before finishing the day 8.45% higher at $0.34. A total of 1.06 million shares were traded, which is below the daily average volume of 1.43 million. The company's stock has lost 3.25% in the last three months, underperforming the S&P 500 which has lost 0.54% during the same period. Given the recent gains, Delcath Systems Inc.'s stock continues to trade below its 50-day and 200-day moving averages. The free technical analysis on DCTH is available by signing up at: http://www.AAAResearchReports.com/DCTH082113.pdf Shares in Astex Pharmaceuticals Inc. edged 0.93% higher on Tuesday, extending their gains from previous trading sessions. The company's shares fluctuated between $5.22 and $5.47 before closing the day at $5.43. A total of 0.69 million shares were traded, which is below the daily average volume of 1.26 million. Astex Pharmaceuticals' shares have gained 5.44% in the last three trading sessions, outperforming the S&P 500 which has lost 0.54% during the same period. Additionally, the stock is trading above its 50-day and 200-day moving averages. Register now to download free research on ASTX at: http://www.AAAResearchReports.com/ASTX082113.pdf Shares in BioMarin Pharmaceuticals Inc. rose sharply on Tuesday, finishing the day at $63.85, up 1.70% from its previous closing price of $62.78. The company's shares oscillated between $62.46 and $63.99. A total of 0.91 million shares were traded, which is below the daily average volume of 1.33 million. The stock has gained 2.27% in the last three months, compared to a loss of 0.84% in the S&P 500 during the same period. Moreover, the BioMarin Pharmaceutical's shares are currently trading above their50-day and 200-day moving averages. A free report on BMRN can be accessed by registering at: http://www.AAAResearchReports.com/BMRN082113.pdf Akorn Inc.'s shares fluctuated between $16.08 and $16.41 before finishing the day 1.05% higher at $16.32. A total of 0.40 million shares were traded, which is below the daily average volume of 0.56 million. The company's shares have gained 16.99% in the last one month and 10.05% in the last three months, outperforming the S&P 500 which has lost 2.35% and 0.84% during the respective periods. Furthermore, the company's shares are trading above the 50-day and 200-day moving averages. Register with AAA Research Reports and download research on AKRX for free at: http://www.AAAResearchReports.com/AKRX082113.pdf ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA ® charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. AAAresearchreports.com SOURCE AAA Research Reports Contact: Phone #: +1-(646)-396-9126, Contact Name: Peter F. Jones, Email ID: email@example.com
Pre-Market Review: Delcath Systems Inc., Astex Pharma Inc., BioMarin Pharma Inc., and Akorn Inc.